<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394095</url>
  </required_header>
  <id_info>
    <org_study_id>F1D-MC-X304</org_study_id>
    <nct_id>NCT00394095</nct_id>
  </id_info>
  <brief_title>Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Pilot Study of Topiramate vs. Placebo in Combination With Olanzapine for the Prevention of Weight Gain in Manic or Mixed Youth With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the efficacy of topiramate in combination
      with olanzapine for the prevention of weight gain in youth with bipolar disorder. The
      secondary objective is to examine the tolerability of topiramate in combination with
      olanzapine for the prevention of weight gain in youth with bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consent and screening, patients will be initiated on 5mg or 10mg per day of olanzapine.
      Olanzapine doses will be titrated to 10-20 mg of olanzapine over one week, to a maximum of
      20mg by day 21. Patients will also receive either topiramate (25mg bid titrated over 18 days
      to 150 mg bid. with flexibility to titrate to 200mg bid) or matched placebo. Topiramate will
      be initiated at a dose of 25 mg bid and will be increased by 25 mg bid every three days as
      tolerated. Patients will be evaluated by a blinded (to treatment status and adverse events)
      rater.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>For all participants, BMI was computed using Change in BMI [kg/m2 (weight/height2)] over 12 weeks from Baseline to Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>For all participants, change in body weight in kg over 12 weeks from Baseline to Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Topiramate</measure>
    <time_frame>12 weeks</time_frame>
    <description>To examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Weight Gain</condition>
  <arm_group>
    <arm_group_label>Topiramate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Oral topiramate 300-400mg/day for 12 weeks</description>
    <arm_group_label>Topiramate Group</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo to Experimental arm</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, ages 10-18 years.

          2. Female patients of menarche must be using a medically accepted means of contraception
             (e.g. oral contraceptives, Depo-Provera, abstinence).

          3. Each patient's authorized legal guardian must understand the nature of the study and
             must provide written informed consent. Each patient must also give assent to study
             participation.

          4. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (DSM-IV-TR) bipolar disorder, type I and currently display
             an acute manic or mixed episode as determined by K-SADS (Geller et al 2000).

          5. Patients must have a baseline (day 0) Young Mania Rating Scale score of at least 16.

          6. Subjects should be fluent in English.

        Exclusion Criteria:

          1. Female patients who are either pregnant or lactating.

          2. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory,
             cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical
             conditions.

          3. Any history of current or past diabetes that has been treated with pharmacological
             intervention.

          4. Neurological disorders including epilepsy, stroke, or severe head trauma.

          5. Clinically significant laboratory abnormalities (&gt; 3 times upper limit of normal), on
             any of the following tests: CBC with differential, electrolytes, BUN, creatinine,
             hepatic transaminases, lipid profile, fasting glucose, urinalysis, or thyroid indices.
             Clinically abnormal ECG.

          6. Manic or mixed episode due to a general medical condition or substance-induced mania
             (DSM-IV-TR).

          7. Mental retardation (IQ &lt;70).

          8. History of hypersensitivity to or intolerance of olanzapine or topiramate.

          9. Prior history of olanzapine or topiramate non-response or allergic reaction.

         10. DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months.

         11. Judged clinically to be at suicidal risk (defined as having active suicidal ideation,
             intent or plan, or a serious suicide attempt within 30 days, or a baseline Children's
             Depression Rating Scale suicide score of &gt;3).

         12. Treatment with an injectable depot neuroleptic within less than one dosing interval
             between depot neuroleptic injections and day 0.

         13. Treatment with concurrent mood stabilizers or anticonvulsants, benzodiazepines (except
             as described below), psychostimulants, guanethidine, or guanadrel, or antidepressants.

         14. Schizophrenia or other psychotic disorders (including schizophreniform disorder,
             schizoaffective disorder, delusional disorder, brief psychotic disorder, shared
             psychotic disorder, psychotic disorder due to a general medical condition,
             substance-induced psychotic disorder, psychotic disorder not otherwise specified) as
             defined in the DSM-IV.

         15. Major depressive disorder, dysthymic disorder, depressive disorder not otherwise
             specified.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa P DelBello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <results_first_submitted>March 23, 2011</results_first_submitted>
  <results_first_submitted_qc>April 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Melissa Delbello</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Weight Gain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty one bipolar adolescents with a manic or mixed episode (ages 12-18 years) were recruited from the inpatient units and outpatient clinics at the University of Cincinnati and Cincinnati Children’s Hospital Medical Center.</recruitment_details>
      <pre_assignment_details>Subjects meeting the entry criteria were randomized to treatment with topiramate or placebo in combination with olanzapine for this 12-week study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental Group: Topiramate Group</title>
          <description>Experimental Group Receiving oral Topiramate, 300-400mg/day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Comparator Group: Placebo Group</title>
          <description>Placebo Group Receiving oral placebo 300-400mg/day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screened</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Group: Topiramate Group</title>
          <description>Experimental Group Receiving oral Topiramate, 300-400mg/day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Comparator Group: Placebo Group</title>
          <description>Placebo Group Receiving oral placebo 300-400mg/day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="1.9"/>
                    <measurement group_id="B2" value="14.0" spread="2.0"/>
                    <measurement group_id="B3" value="14.3" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>For all participants, BMI was computed using Change in BMI [kg/m2 (weight/height2)] over 12 weeks from Baseline to Week 12.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was per protocol based on change in BMI over 12 weeks in the Experimental sample (N=16) compared to the Placebo group (N=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group: Topiramate Group</title>
            <description>Change in Body Weight in kilograms over 12 weeks in the Experimental Topiramate sample (N=16) compared to the Placebo group (N=14).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Group receiving comparable dosage of placebo over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>For all participants, BMI was computed using Change in BMI [kg/m2 (weight/height2)] over 12 weeks from Baseline to Week 12.</description>
          <population>The analysis was per protocol based on change in BMI over 12 weeks in the Experimental sample (N=16) compared to the Placebo group (N=14).</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-.33" upper_limit="2.33"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.20" upper_limit="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Topiramate</title>
        <description>To examine the tolerability of topiramate in combination with olanzapine for the prevention of weight gain in youth with bipolar disorder.</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>For all participants, change in body weight in kg over 12 weeks from Baseline to Week 12.</description>
        <time_frame>12 weeks</time_frame>
        <population>Bipolar youth (ages 12-17) who were taking olanzapine (10-20 mg/day) for a manic episode, were given topiramate (300-400mg/day) or comparable dose placebo for 12 weeks. Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group: Topiramate Group</title>
            <description>Change in Body Weight in kilograms over 12 weeks in the Experimental Topiramate sample (N=16) compared to the Placebo group (N=14).</description>
          </group>
          <group group_id="O2">
            <title>Comparator Group: Placebo Group</title>
            <description>Group receiving comparable dosage of placebo over 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>For all participants, change in body weight in kg over 12 weeks from Baseline to Week 12.</description>
          <population>Bipolar youth (ages 12-17) who were taking olanzapine (10-20 mg/day) for a manic episode, were given topiramate (300-400mg/day) or comparable dose placebo for 12 weeks. Analysis was per protocol.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.85" upper_limit="14.95"/>
                    <measurement group_id="O2" value="6.4" lower_limit="0.85" upper_limit="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Group: Topiramate Group</title>
          <description>Experimental Group Receiving oral Topiramate, 300-400mg/day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Comparator Group: Placebo Group</title>
          <description>Placebo Group Receiving oral placebo 300-400mg/day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Hyperthermia</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One subject experienced hyperthermia and was admitted to hospital. Subject was discontinued from study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa DelBello, MD</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-4489</phone>
      <email>melissa.delbello@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

